Fig. 7.

Activation of PYK2 is required for ATRA-mediated CD38 upregulation. A Kinase profiling of SP-53 cells treated with ATRA. SP-53 cells were treated with vehicle or ATRA (10 nM). 1–6, kinases; 7, reference spot; 8, negative control. The fold of phosphorylation upon ATRA over vehicle was shown on the right. B CD38 expression in SP-53 cells treated with ATRA or kinase inhibitors. SP-53 cells were treated with ATRA (10 nM) and/or kinase inhibitors for 48 h and subjected to flow cytometry with an anti-CD38 antibody. C mRNA levels of CD38 in SP-53 with or without treatment of ATRA (10 nM) or PF-431396. D SP-53 cells were treated with ATRA (10 nM) or PF-431396 for 48 h; CD38, PYK2, and p-PYK2 expression were evaluated by immunoblotting